期刊文献+

高效液相色谱-质谱联用法测定血浆富马酸卢帕他定浓度 被引量:4

Determination of Plasma Concentration of Rupatadine Fumarate by HPLC-MS/MS
下载PDF
导出
摘要 目的建立高效液相色谱一质谱联用(HPLC-MS/MS)法测定人血浆富马酸卢帕他定浓度。方法以氯雷他定为内标,待测血浆样品经氢氧化钠碱化,加醋酸乙酯-二氟甲烷(4:1)萃取后,用液-质联用方法进行检测。结果血浆富马酸卢帕他定的浓度线性范围为0.05—13.00μg·L^-1,最低定量浓度为0.05μg·L^-1;提取回收率为65.06%-73.25%。结论该法分离效果良好,灵敏度高,回收率高,可用于人体血药浓度测定及药动学研究。 Objective An HPLC-MS/MS method was established for the determination of rupatadine fumarate in plasma. Methods The drug and internal standard (loratadine)in plasma were alkalified with sodium hydroxide, extracted with acetic ether-dichloromethane (4 : 1 ) and detected by HPLC-MS/MS. Results A good linearity of rupatadine fumarate in plasma was obtained from 0.05 to 13 μg · L^-1 , the minimum level of which was 0.05 μg · L^-1 and the recovery rate was from 65.06% to 73.25%. Conclusion The method is sensitive, accurate and reliable, and could be used for determing drug concentration and pharmacokinetic of rupatadine fumarate.
出处 《医药导报》 CAS 2008年第10期1174-1176,共3页 Herald of Medicine
关键词 卢帕他定 高效液相色谱-质谱联用 血药浓度 Rupatadine HPLC-MS/MS Plasma drug level
  • 相关文献

参考文献4

  • 1IZQUIERDO I, MERLOS M, GARCIA R. Rupatadine, a new selective histanine H1 receptor and pletelet-activatig fator (PAF) antagonist [ J ]. Drugs Today , 2003,39 ( 6 ) : 451 - 458. 被引量:1
  • 2VLASE L, IMRE S, MUNTEAN D, et al. Determination of loratadine and its active metabolite in human plasma by high performance liquid chromatography with mass spectrometry detection[ J]. Pharm Biomed Anal,2006, [ Epub ahead of print]. 被引量:1
  • 3WEN Y G, YU L H, PENG J L, et al. Sensitive liquid chromatography electrospray ionization ion-trap mass spectrometry for the determination of rupatadine in human plasma[J]. J Chin Pharm Sci, 2007,42(16) : 84 -89. 被引量:1
  • 4曾经泽..生物药物分析[M],1998.

同被引文献27

  • 1卜今,陈志强.卢帕他定——新型的组胺H1受体和血小板活化因子受体双重拮抗剂[J].中国中西医结合皮肤性病学杂志,2006,5(3):182-184. 被引量:7
  • 2吕静静,陈峰,崔永春,王守仓,张爱民,李仁鹏,许金珂.个体生物等效性检验的样本含量估计[J].中国临床药理学与治疗学,2007,12(2):204-207. 被引量:4
  • 3Stuebner P, Horak F, Zieglmayer R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber[J]. Ann Allergy Asthma Immunol, 2006,96(1) :37-44. 被引量:1
  • 4Barbanoj MJ, Garcia-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers[J].Hum Psychopharmacol, 2006, 21(1):13-26. 被引量:1
  • 5Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis[J]. Drugs Today (Bare), 2003,39(6) :451-468(Review). 被引量:1
  • 6Tian Y, Zhang J, Lin H, et al. High performance liquid chromatography-tandem mass spectrometric determination of rupatadine in human plasma and its pharmacokinetics[J]. Pharm Biomed Anal, 2008,47 (4/5) :899-906. 被引量:1
  • 7黄钦,魏春敏.浅谈高变异药物的生物等效性研究[J].中国临床药理学与治疗学,2007,12(8):841-844. 被引量:15
  • 8BARBANOJ MJ, GARCIA-GEA C, MORTE A. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet- activating factor antagonist, at different doses in healthy volunteers[J]. Neuropsychobiology, 2004, 50(4) : 311-321. 被引量:1
  • 9MION ODE G, CAMPOS RA, ANTILA M. Futura study:evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis[J].Braz J Otorhinolaryngol. 2009, 75(5): 673-679. 被引量:1
  • 10BARBANOJ MJ, GARCIA-GEA C, ANTONUOAN R, et al. Evaluation of the cognitive, psychoinotor and pharmaeokinetics profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers[J]. Hum Psychopharmacol,2006, 21(1). 13-26. 被引量:1

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部